Information Provided By:
Fly News Breaks for February 15, 2017
BIIB, BIIV
Feb 15, 2017 | 08:26 EDT
Leerink analyst Jason Gerberry initiated Bioverativ (BIVV) with an Outperform rating and $56 price target, citing the "underappreciated durability" of its marketed hemophilia assets, near-term projections that he views as beatable and the potential for tax reform or an M&A deal to unlock value. Bioverativ recently spun off from Biogen (BIIB) and "spins have a history of working," Gerberry added.
News For BIIV;BIIB From the Last 2 Days
There are no results for your query BIIV;BIIB